COVID-19 convalescent plasma (University of Virginia)

COVID-19 convalescent plasma (University of Virginia) is an investigational passive antibody immunotherapy developed for the treatment of hospitalized patients with COVID-19. The therapy utilizes high-titer convalescent plasma collected from donors who have recovered from SARS-CoV-2 infection. These plasma units contain neutralizing antibodies that specifically target and bind to SARS-CoV-2 virus particles, thereby preventing the virus from entering and infecting host cells. The University of Virginia evaluated this therapy in a Phase II clinical trial (CIP-T) focusing on patients with acute respiratory symptoms to determine if early administration could reduce the risk of intensive care unit (ICU) admission and mortality. The plasma used in the study was sourced from the American Red Cross and the New York Blood Center and underwent pathogen reduction to ensure safety.

Other names

High-Titer Anti-SARS-CoV-2 Convalescent Plasmaanti-SARS-CoV-2 convalescent plasmaanti-SARS-CoV2 convalescent plasmaanti-SARS-CoV 2 convalescent plasmaPathogen reduced SARS-CoV-2 convalescent plasma